...
ARWRMID

Arrowhead Pharmaceuticals, Inc.

HealthcareBiotechnology
$63.27
$0.00(-0.19%)
52W$9.57
$76.76
FinancialsValuationvs ALNY
Updated Mar 1, 12:00 AM
RSI47
RS Rating96/99
Beta1.67
Volatility72%
F-Score5/9
Mkt Cap$8.7B
EMERGING TREND

Price Action

5Y Daily
50 DMA150 DMA200 DMA

Technical Summary

EMERGING TREND

Arrowhead Pharmaceuticals, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 96), indicating clear outperformance against the broad market. Earnings growth of 116% provides fundamental context to the price action. Investors should exercise caution due to high volatility (72% annualized), which requires wider risk management.

Relative Strength
96
out of 99
Market Leader
Trend Score
3/4
Minervini Criteria
EMERGING TREND
Risk (Beta)
1.67
vs S&P 500
HIGH BETA
52W Position
80%
from 52W low
Mid Range
Trend & Momentum Analysis

Trend Template (Minervini)

EMERGING TREND3/4 Criteria Met
CriterionValueStatus
Price > 50 SMA$66.15
50 SMA > 100 SMA$56.23
100 SMA > 150 SMA$45.77
150 SMA > 200 SMA$38.41

Price vs Moving Averages

PeriodValueSpreadSignal
20 SMA$64.77-2.32%BELOW
50 SMA$66.15-4.35%BELOW
100 SMA$56.23+12.53%ABOVE
150 SMA$45.77+38.25%ABOVE
200 SMA$38.41+64.70%ABOVE

Price Performance

1D-0.2%
1W+0.2%
1M-3.5%
3M+20.1%
6M+183.2%
YTD-6.7%
1Y+234.6%
3Y+25.1%
52-Week Trading Range80% from low
$63.27
52W Low$9.57
52W High$76.76

Technical Indicators

RSI (14)NEUTRAL
46.7
305070
VCP ScoreCOOL
6/10
Base depth: 28.7%

Risk Profile

Beta
1.67
52W Vol
72%
ATR
$2.56
Max DD (1Y)
-47%

Volume Analysis

Today
63
50D Avg
2.54M
Vol Ratio
0.00x
Liquidity
LIQUID

Earnings Momentum

Q2'25+370%
$2.75
Q3'25+9%
$-1.26
Q4'25+88%
$-0.17
Q1'26+116%
$0.22
Fundamentals & Growth

Growth Trends

Compounded Sales Growth

10 Years:+115.61%
5 Years:+56.63%
3 Years:+50.52%
TTM:+40.82%

Compounded Profit Growth

10 Years:—
5 Years:—
3 Years:—
TTM:+129.67%

Stock Price CAGR

10 Years:+32.13%
5 Years:-5.46%
3 Years:+25.12%
1 Year:+234.58%

Return on Equity

10Y Avg:-54.9%
5Y Avg:-76.9%
3Y Avg:-103.1%
Last Year:35.9%

Key Metrics

Market Cap$8.7B
Gross Margin97.1%
Net Margin-0.2%
Piotroski F-Score5/9

More ARWR Analysis

Full Financial AnalysisDCF & Intrinsic ValueTotal Return Calculator

Compare With

ARWR vs ALNYALNYIONSCRSPBEAM

Data Dictionary

RS Rating (Relative Strength)

Measures 12-month price performance vs all stocks. Rating of 96 meansARWR outperformed 96% of all stocks. Scores >80 indicate market leaders.

Beta

Measures volatility vs S&P 500. Beta of 1.67 means 67% more volatile than market.

Piotroski F-Score

9-point financial strength score based on profitability, leverage, and efficiency. Score of 5/9. Scores 7-9 = strong, 4-6 average, 0-3 = weak.

VCP (Volatility Contraction Pattern)

Measures base formation quality. Higher scores indicate tighter consolidation near pivot points. Score of 6/10 with COOL status.

Frequently Asked Questions

Is ARWR in an uptrend right now?

ARWR has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.

Is ARWR overbought or oversold?

ARWR's RSI (14) is 47. The stock is in neutral territory, neither overbought nor oversold.

Is ARWR outperforming the market?

ARWR has a Relative Strength (RS) Rating of 96 out of 99. Yes, ARWR is a market leader, outperforming 96% of all stocks over the past 12 months.

Where is ARWR in its 52-week range?

ARWR is trading at $63.27, which is 82% of its 52-week high ($76.76) and 80% above its 52-week low ($9.57).

How volatile is ARWR?

ARWR has a Beta of 1.67 and 52-week volatility of 72%. It's more volatile than the S&P 500 - expect bigger swings.